Newsletter

Malaysia: Amendment Regulations 2025 [P.U. (A) 330] – Class A Change Payment Fee – October/November 2025

Malaysia: Amendment Regulations 2025 [P.U. (A) 330] – Class A Change Payment Fee – October/November 2025

  • 2025-11-21 08:14:15

The Malaysian Medical Device Authority (MDA) has issued the Medical Device (Amendment) Regulations 2025 [P.U.(A) 330], which were gazetted on 11 September 2025. This amendment revises the fee structure for registrations of Class A medical device effective on or after 1 January 2026. Stakeholders are advised to review the changes and plan their submissions accordingly to ensure timely compliance.

More
USA: Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions - August/September 2025

USA: Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions - August/September 2025

  • 2025-09-24 07:20:49

The FDA has issued draft guidance on marketing submissions for AI-enabled device software functions (AI-DSFs), with a focus on using a predetermined change control plan (PCCP). A PCCP allows manufacturers to plan and manage software changes in a predictable and controlled way, making regulatory review smoother and device performance more reliable.

More
Thailand: Updated Change Notification Guidelines for IVD and Non-IVD: Model Additions/Removals and Amendments to Thai Establishment Information on Labels – March/April 2025

Thailand: Updated Change Notification Guidelines for IVD and Non-IVD: Model Additions/Removals and Amendments to Thai Establishment Information on Labels – March/April 2025

  • 2025-03-25 10:37:19

The Thai FDA updated its change notification guidelines, effective 15 January 2025, focusing on model additions/removals and importer/manufacturer info updates for both IVD and non-IVD devices. The update allows modifications to groupings when adding or removing products within the same application. Additionally, adding models is now classified as a Major Change, requiring an extensive documentation.

More
Singapore: Pilot Run: Change Management Program (CMP) for SaMD, including Machine Leaning-enabled SaMD – January/February 2025

Singapore: Pilot Run: Change Management Program (CMP) for SaMD, including Machine Leaning-enabled SaMD – January/February 2025

  • 2025-01-22 03:51:46

Medical Device Cluster (MDC) is rolling out the pilot run for the Change Management Program (CMP) for Software as Medical Device (SaMD), also known as a Standalone medical mobile application, including Machine Learning-Enabled SaMD. The program is voluntary and incorporated into HSA's existing Premarket Product Registration and Change Notification process. With effect from 4 December 2024, HSA also published new guidance document (GN-37) for the program.

More
Singapore: Consultation on Guidance of Change Management Program (CMP) for SaMD – September/October 2024

Singapore: Consultation on Guidance of Change Management Program (CMP) for SaMD – September/October 2024

  • 2024-10-10 08:46:48

HSA's Medical Devices Cluster has released a draft of Guidance on Change Management Program (CMP) for stakeholders with consultation period from 26 August 2024 to 21 October 2024. The new optional regulatory pathway aims to accommodate the rapid iterative nature of SaMD changes. This guidance explains on the CMP definition, scope, eligibility, requirements, and process. The guidance also introduces the concept of 'Pre-specified' changes. Feedback on the guidance draft can be sent to HSA through email by using prescribed feedback form.

More
MALAYSIA: MDA/GD/0067: POST MARKET INFORMATION EXCHANGE FOR ASEAN MEMBER STATES –MARCH/APRIL 2024

MALAYSIA: MDA/GD/0067: POST MARKET INFORMATION EXCHANGE FOR ASEAN MEMBER STATES –MARCH/APRIL 2024

  • 2024-04-03 09:34:09

The Medical Device Authority (MDA) published new Guidance Document, on “POST MARKET INFORMATION EXCHANGE FOR ASEAN MEMBER STATES”, on January, 2024. This document serves as guidance on exchange of post market information among AMS.
In order to maintain patient safety and public health, it is necessary that all medical devices that are placed in the market meet appropriate standards of safety, quality and performance, and that they are used safely.

More